InTandem Capital Partners Invests in Clinilabs to Accelerate CNS Drug and Device Development
InTandem Capital Partners, a private equity firm specializing in healthcare services, has announced a strategic partnership with Clinilabs, a global full-service contract research organization (CRO). This collaboration aims to support Clinilabs’ continued growth in the development of drug and device therapies for central nervous system (CNS) disorders. The partnership involves the firm working closely with Clinilabs’ founder and management team to propel the company’s future expansion.
Clinilabs: A Leader in CNS Drug Development
Since its inception in 2000, Clinilabs has positioned itself as a pioneer in neuroscience therapeutics, exclusively focusing on neurology, psychiatry, addiction, and rare CNS disorders. Over the years, the company has earned a reputation for its specialized expertise and commitment to advancing CNS clinical trials. Clinilabs has successfully managed over 750 CNS clinical trials and has contributed to the approval of 22 new therapies spanning 13 different CNS indications.
Gary Zammit, Ph.D., President & CEO of Clinilabs, expressed his enthusiasm about the partnership with InTandem, stating, “I am pleased to announce that Clinilabs has partnered with InTandem to pursue the next stages of our growth. Clinilabs’ decision to partner came down to the people at InTandem. They share our vision for the company, have deep expertise in the sector, and provide value-added operational resources that we sought to build our company.”
Proven Track Record in CNS Therapeutics
Clinilabs has been a key player in advancing CNS therapeutics, particularly through its successful clinical trials and its expertise in regulatory compliance. The company has routinely passed audits conducted by global regulatory bodies, including the FDA, EMA, PMDA, and sFDA, reinforcing its reputation as a high-quality, therapeutically focused CRO. Clinilabs’ global presence and its ability to execute complex clinical trials have made it a trusted partner for pharmaceutical, biotechnology, and medical device companies seeking to develop CNS-related therapies.
InTandem Capital’s Vision for Growth
Mehran Ahmed, Partner at InTandem Capital, expressed confidence in Clinilabs’ capabilities and highlighted the growing market for CNS therapeutics. “As the market for CNS therapeutics continues to grow, it is essential for sponsors to work with a CRO that understands the unique challenges that come with neuroscience clinical trials,” said Ahmed. “InTandem recognizes Clinilabs’ deep expertise, and we are thrilled to collaborate with Gary and his talented team. We look forward to supporting the company in delivering high-quality, timely, and cost-effective drug and device development services that will accelerate the availability of new CNS therapeutics to the patients who need them most.”
InTandem Capital’s expertise in the healthcare sector, combined with Clinilabs’ established reputation, positions the two organizations for success. This partnership will help Clinilabs expand its service offerings and continue making an impact on the development of life-changing CNS therapies.
Comprehensive Services for CNS Drug and Device Development
Clinilabs provides a full spectrum of services that cover the entire drug development lifecycle—from first-in-human trials to Phase 3 studies. These services include trial management, feasibility and site selection, risk-based monitoring, data management, core laboratories, biostatistics, medical writing, and trial execution at both wholly-owned units and independent investigator sites around the world.
This comprehensive approach ensures that Clinilabs can support sponsors in all stages of CNS drug and device development, offering expertise in both clinical trial execution and regulatory compliance. The company’s ability to handle the complexities of CNS trials is one of the reasons it is highly regarded by its clients.
A Shared Commitment to Improving Patient Outcomes
Eileen McAuley, Chief Operating Officer at Clinilabs, reflected on the exciting future of the company following the partnership with InTandem. “This is an especially exciting time for our organization’s future. Our team remains focused on the ultimate measure of our success—improving the lives of patients who are fighting battles against central nervous system disorders,” said McAuley.
As the demand for new CNS therapies continues to grow, Clinilabs’ strategic partnership with InTandem will help ensure that the company remains at the forefront of clinical trial research, supporting the development of innovative treatments that can transform patients’ lives.
Looking Ahead: A Promising Future for CNS Therapeutics
The collaboration between InTandem Capital and Clinilabs is set to usher in a new chapter in CNS drug and device development. By combining InTandem’s operational expertise with Clinilabs’ deep knowledge of neuroscience therapeutics, this partnership is poised to help accelerate the development of new treatments for patients suffering from CNS disorders.
As the healthcare landscape continues to evolve, the need for specialized CROs like Clinilabs will only increase. With the support of InTandem Capital, Clinilabs is well-positioned to continue expanding its offerings and play a key role in advancing the field of CNS therapeutics.
Conclusion: A Strong Partnership for the Future
InTandem Capital’s strategic investment in Clinilabs underscores the growing importance of specialized CROs in the development of CNS therapies. With a proven track record of success and a commitment to patient outcomes, Clinilabs is poised to continue its leadership in the industry. The partnership with InTandem Capital will provide the company with the resources and expertise needed to expand its capabilities and bring new, life-changing CNS therapeutics to market.
About InTandem Capital Partners
InTandem Capital Partners is a private equity firm that invests in and helps accelerate the growth of select healthcare services companies. Its goal is to build excellent businesses of significant value by working collaboratively with its management team partners. InTandem is solely focused on investing in businesses that align closely with the Healthcare Quintuple Aim – the simultaneous pursuit of enhanced patient experience, elevated provider experience, improved clinical outcomes, greater healthcare equity, and lower cost of care delivery.
The firm is comprised of former business executives and experienced investors and is uniquely qualified to provide strategic, acquisition, and operating expertise to help companies significantly increase their value and their contribution to an improved healthcare system. InTandem provides active support to the management of its portfolio companies directly and leverages its network of industry executives to augment its capabilities. For further information, please visit: www.intandemcapital.com.
About Clinilabs
Clinilabs is a global, full-service contract research organization focused exclusively on CNS drug, device, and technology development. With deep expertise in CNS, Clinilabs is committed to developing therapies that address a range of psychiatric, neurological, and substance use disorders, as well as rare and ultra-rare CNS diseases. Clinilabs partners with pharmaceutical, biotechnology, and medical device companies to provide a comprehensive spectrum of high-quality, timely, and cost-effective clinical drug development services from first-in-human to Phase 3 trials, all aimed at accelerating the availability of new CNS therapies in the market.
Since 2000, Clinilabs has conducted more than 750 CNS clinical trials and has been instrumental in the approval of 22 new therapies across 13 CNS indications, significantly impacting the lives of patients worldwide. For further information, please visit www.clinilabs.com.
